Robyn Karnauskas

Stock Analyst at Truist Securities

(0)
# 3781
Out of 5,240 analysts
215
Total ratings
35.82%
Success rate
-0.77%
Average return
44 Stocks
Name Action Price Target Current % Upside Ratings Updated
Amgen
Maintains: Hold
333 298
270.74 10.07% 12 Jan 8, 2025
Bristol-Myers Squibb
Maintains: Strong Buy
62 65
56.27 15.51% 2 Jan 8, 2025
Merck & Co
Downgrades: Hold
130 110
100.32 9.65% 11 Jan 8, 2025
Gilead Sciences
Maintains: Hold
82 83
91.91 -9.69% 15 Aug 15, 2024
AbbVie
Reiterates: Strong Buy
195 210
172.33 21.86% 8 Jul 26, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Hold
n/a
n/a n/a 3 Jun 11, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
340 340
145.32 133.97% 17 May 16, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
26 26
3.21 709.97% 2 May 15, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
8 7
1.45 382.76% 13 May 13, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
1135 1135
698.75 62.43% 16 Apr 3, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
10
3.32 201.2% 2 Mar 26, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
9 9
2.81 220.28% 4 Mar 26, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
74
18.98 289.88% 2 Mar 25, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
23
11.08 107.58% 5 Mar 25, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
48
23.74 102.19% 5 Mar 25, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
50
14.26 250.63% 8 Mar 25, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
850
752.59 12.94% 4 Mar 22, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
456 508
419.49 21.1% 12 Jan 31, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
42 36
26.54 35.64% 5 Dec 14, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
29
n/a n/a 1 Oct 10, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Hold
25
43.22 -42.16% 1 Oct 6, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Hold
n/a
n/a n/a 6 Oct 5, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
140
63.73 119.68% 5 Sep 25, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
150
1.07 13918.69% 2 Sep 6, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Hold
7
1.33 426.32% 3 Aug 16, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
65 55
13.89 295.97% 1 May 11, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Hold
n/a
n/a n/a 4 Dec 6, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
29
2.97 876.43% 1 Nov 16, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
500 320
20.65 1449.64% 2 Aug 23, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
10 15
8 87.5% 5 Aug 9, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
12 4
n/a n/a 2 Mar 31, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Hold
65 10
n/a n/a 5 Nov 8, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Hold
32
n/a n/a 4 Aug 6, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Hold
580 120
n/a n/a 1 Mar 2, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
25
3.69 577.51% 1 Nov 11, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
85
0.69 12218.84% 1 Oct 8, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
180 165
n/a n/a 5 May 23, 2019
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
100 77
n/a n/a 6 Dec 17, 2018
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
60 44
n/a n/a 3 Aug 20, 2018
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
44 63
n/a n/a 3 Mar 1, 2018
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Buy
n/a
n/a n/a 3 Feb 16, 2018
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
n/a
n/a n/a 2 Jan 18, 2018
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
62 87
n/a n/a 1 Mar 2, 2017
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Neutral
6 8
n/a n/a 1 Mar 3, 2016